Sign Out
Pregnancy: In pregnant animals, rivastigmine and/or metabolites crossed the placenta. It is not known if this occurs in humans. No clinical data on exposed pregnancies are available. In peri/postnatal studies in rats, an increased gestation time was observed. Rivastigmine should not be used during pregnancy unless clearly necessary.
Breast-feeding: In animals, rivastigmine is excreted in milk. It is not known if rivastigmine is excreted into human milk. Therefore, women on rivastigmine should not breast-feed.
Fertility: No adverse effects of rivastigmine were observed on fertility or reproductive performance in rats (see Pharmacology: Toxicology: Preclinical safety data under Actions). Effects of rivastigmine on human fertility are not known.
